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Abstract 
The synthetic utility of europium complexes with three coordinated 4-bromopyridyl groups 
for chromophore elaboration has been assessed in palladium-catalysed Sonogashira coupling 
reactions,  and in copper(I) mediated click reactions of the triazide derivative, generated in 
situ. The crystal structure of the Eu complex of a p-OMe-phenyl substituted triazole at 100K 
is reported in which the pendant triazole sensitising moieties interdigitate in the solid-state 
lattice. The triazole complex can be separated into  and  enantiomers by chiral HPLC but 
is weakly emissive in methanol ( 5.5 mM-1cm-1; exc 320 nm;  0.2%), contrasting with a set 
of four alkynyl-aryl derivatives which are one thousand times brighter and absorb strongly 
with broad absorption maxima in the range 332 to 360 nm. An enantiopure europium 
complex gives an intense CPL signal in solution that is the strongest yet reported.  
 
 
Introduction 
In the synthesis of metal coordination complexes, it is most common to introduce the metal 
centre in the final step. This approach is often used in order to simplify the preparation and 
purification of ligand intermediates in non-polar media,  and because many functionalisation 
reactions involve rather harsh reactions conditions under which dissociation of the metal ion 
may occur, e.g. extremes of pH. An alternative strategy seeks to identify a robust metal 
coordination complex that can serve as a late intermediate in the synthesis of the target 
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complex, bearing an appropriate functional group (or groups) that can be modified or 
elaborated under relatively mild conditions. Examples of this divergent approach can be 
found in several different areas of coordination chemistry with kinetically inert metal 
complexes. For example, Williams has used a variety of Suzuki coupling reactions with 
iridium(III) complexes bearing aryl bromide functionality, either to extend ligand conjugation 
or create multimeric systems. 
1,2
 In lanthanide systems, modular syntheses of heterometallic 
complexes have been devised by using kinetically stable complexes of heptadentate and 
octadentate ligands, in a series of Ugi, Pd(0) or Cu(I) catalysed ‘click’ reactions. 3-6 There are 
also many examples to be found in contrast agent research, where Gd complexes of 
octadentate ligands, with between one and four peripheral functional groups, serve as 
intermediates in the synthesis of higher molecular weight conjugates. Typically, these 
examples involve amide bond formation or coordination of a pendant chelate to a second 
metal ion. 
7-10  
 
 
In the development of emissive lanthanide optical probes, it is particularly attractive to devise 
a kinetically stable and synthetically versatile precursor complex that can be modified easily, 
as this approach allows systematic changes in the structure of the sensitising chromophore to 
be undertaken at the end of the synthesis. This divergent strategy contrasts with the linear 
synthetic approaches usually adopted, wherein a single sensitising moiety is engineered into 
the ligand at the beginning of the synthesis. It allows systematic variations to be made that 
permit an optimisation of the absorption properties (max and ), whilst retaining the common 
coordination environment about the lanthanide ion that primarily determines the chemical 
stability of the complex and its resistance to excited state quenching.  
 
Owing to their line-like emission spectra, large Stokes’ shifts and long-lived excited states, 
emissive lanthanide complexes are proving to be excellent probes of biological systems and 
fluids. 
11-19
   Recently, a series of very bright Eu(III) phosphinate and carboxylate complexes 
has been reported containing pyridyl-alkynyl-aryl chromphores (Fig. 1). 
12
 These bright 
complexes ( ~ 60 mM-1cm-1 and em in the range 20 to 50%), possess broad absorption 
bands with max ~ 330 to 350 nm, meaning they can be excited using lasers or light emitting 
diodes at 337, 355, 365 or 375 nm, as required for use in cellulo.  The peripheral 
functionalization of a second generation of complexes, has allowed for the staining of 
specific cell organelles, and time-resolved microscopy and spectral imaging studies have 
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been investigated. 
13 
A simple retrosynthetic analysis of these systems (Fig. 1) reveals that the 
tris(4-bromopyridine) complex, [Eu.L
1
] can serve as a common late intermediate and be used 
to prepare a wide range of analogues, via palladium-catalysed C-C bond forming reactions to 
sp
2
 or sp hybridised carbon centres. 
 
  
 
 Figure 1  Retrosynthetic analysis of tris-pyridyl-alkynyl-aryl phosphinate complexes  
 
To be used efficiently as stains and probes the complexes should be amenable to structural 
modification, for example to include substituents of varying steric demand, charge centres 
and/or hydrogen bond donors/acceptors, to tune affinity and gain selectivity. The triazole-
forming copper-catalysed alkyne-azide cycloaddition (CuAAC) reaction is an attractive 
chemical reaction that allows such synthetic control,  due to its wide applicability.
20
 The 
tribromo-complex, [Eu.L
1
] can be easily transformed into the corresponding triazide, owing 
to the enhanced electrophilicity of the C-Br bond.  Interestingly, only two examples of 
lanthanide complexes incorporating pyridyl-triazole-aryl acyclic chelating ligands appear in 
the literature (Fig. 2). 
21,22
 Critically, each report states that the complexes have an absorption 
wavelength of 320 nm or more and, in the latter example, sensitised excitation of Eu(III) has 
been demonstrated.  
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 Figure 2  Selected reported pyridyl-triazole-aryl lanthanide complexes 
21,22 
 
In this work, we exemplify the synthetic utility of [Eu.L
1
] in a set of Sonogashira reactions 
that allows the synthesis of four different aralkynyl substituted complexes. In addition, we 
show that substitution of pyridyl-alkynyl-aryl chromophores by pyridyl-triazole-aryl moieties 
allows the creation of a lanthanide complex that can also be excited at the wavelengths used 
in cellular studies. In addition to solution phase characterisation, a single crystal structure 
determination is reported of the triazole complex, [Eu.L
2
], as well as the characterisation of a 
Eu complex, [Eu.L
6
], by circularly polarised luminescence that reveals it to be the brightest 
chiral complex yet observed; it possesses the strongest total CPL signal that has been 
measured.  
 
Results and Discussion 
Synthesis and characterisation of a triazole complex 
A tris-pyridyl-triazole-anisole Eu(III) complex was prepared in a two-step, one-pot sequence 
from the recently reported tris-(4-bromopyridyl) complex, [Eu.L
1
] (Scheme 1).
23
 Substitution 
of the bromide by azide was carried out at room temperature in DMF using excess sodium 
azide. The reaction was quantitative and generated the intermediate triazide complex, which 
was used directly without separation of the excess sodium azide. The second step, the Cu-
catalysed “click” cycloaddition occurred under mild conditions in aqueous DMF, requiring 
the addition of sub-stoichiometric amounts of the accelerant, tris[(1-benzyl-1H-1,2,3-triazol-
4-yl)methyl]amine (TBTA).
1
 
                                                          
1
 Full conversion of the triazide complex to the product tris-triazole was observed by LC-MS. The low isolated 
yield is associated with the efficiency of the chromatographic purification steps.  
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 Scheme 1  Synthesis of the  trispyridyl-triazole-anisole Eu(III) complex, [Eu.L
2
] 
 
The complex was characterized by 
1
H and 
31
P NMR spectroscopy and ES mass spectrometry 
(ESI). The presence of a single peak in the 
31
P NMR spectrum is consistent with the three-
fold complex symmetry in solution. In addition, very small single crystals were grown by 
evaporation of a water/methanol solution of the complex, and were suitable for X-ray 
crystallographic structure determination using synchrotron radiation (Fig. 3). Even after 
taking account of the disorder present in the structure, there is a clear loss in the C3 symmetry 
of the complex in the solid state, as was observed in the structure of a closely related 
europium tris-alkynyl complex, in which P-phenyl substituents replace the P-methyl groups 
in [Eu.L
2
]. 
12
 
 
    
 
Figure 3    The molecular structure of [Eu.L
2
] (ellipsoids are drawn at the 50% probability level;  
  one of the disordered components and the H atoms are omitted for clarity: CCDC 982687).  
 
 Dalton Trans 2014 
 
 
6 
  
 
Figure 4 Views of the packing of [Eu.L
2
] in the crystal lattice (100K), showing the channels in 
  the lattice arising from -stacking of the aryl-substituted chromophores.  
 
 Two “arms” of the molecule [Eu.L2] are essentially flat (the absolute values of minimal 
torsion angles around the bonds, connecting aromatic rings, are less than 8°) while the third 
one is disordered over two positions and noticeably twisted – the average torsion angles 
between pyridyl/triazole and triazole/anisole rings are ca.12° and 33° respectively. Such a 
difference in the conformation of the pendant arms is probably induced by a different crystal 
environment. Indeed, the two flat “arms” form extensive π…π interactions between them, 
while the disordered arm is linked to adjacent molecules only by weaker C-H..π and  C-H…O 
interactions, which operate independently of each other. The combination of all these 
intermolecular interactions results in a quite unusual crystal packing, characterized by the 
presence of wide channels along the crystallographic c-direction (Fig. 4: lower). The size of 
the channels is approximately 13.5Å x 7.5Å and each one contains a significant number of 
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severely disordered solvent molecules. This phenomenon partially explains the poor 
diffracting properties of the crystals of [Eu.L
2
], for which the synchrotron radiation source 
(Diamond) was used to aid data acquisition. 
 
Photophysical characterisations were subsequently undertaken in methanol.
2
 Critically, the 
absorption spectrum reveals that the complex has a broad absorption band at 320 nm, which 
allows for excitation of the complex at wavelengths >340 nm. The europium emission 
spectrum strongly resembles that observed for [Eu.L
1
] and related C3 symmetric aralkynyl 
complexes in solution, as expected. 
12,13 
The interaction between the chromophores evident in 
the packing diagram may help to explain the low overall emission quantum yield of 0.2%, as 
the intermolecular -stacking may enhance charge transfer quenching of the intermediate 
triazole excited states.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
Figure 5  upper: Absorption and emission spectra of [Eu.L
2
], (MeOH, 295K); lower: CPL  spectrum of 
  the J = 1 region showing near mirror image spectra of the (blue: eluting first) and  (red) 
  enantiomers (n.b.  photobleaching occurred during data acquisition, leading to a loss of  
  sensitivity: 10 scans were recorded (1 min each) and summed;  [complex] =  110 mol).  
 
                                                          
2
 This complex was insoluble in pure water; hence, solution characterisation was carried out in methanol. 
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The complex [Eu.L
2
] was analysed by chiral HPLC. The  and  enantiomers were separated 
using a ChiralPAK ID column, with isocratic MeOH as eluent. The separated isomers were 
examined by CPL (exc 320 nm) and near mirror image spectra were observed. This particular 
complex (vide infra) is 1000 times less bright than the alkynyl analogues discussed below, 
and was also rather sensitive to photobleaching during CPL data acquisition, for which ten 
consecutive scans were recorded and averaged.  The sign and sequence of the CPL transitions 
observed were almost identical to those of [Eu.L
1
] and its derivatives and analogues. 
23,24
   
The absolute configuration of the enantiomeric complex that eluted first was therefore 
deduced to be  and, by analogy, it must have an SSS configuration at each chiral P centre 
and a  configuration in each of the three NCH2CH2N chelate rings.   Considering that related 
chiral Ln(III) complexes have been shown to give rise to large circularly polarised 
luminescence (CPL)
24 
 and that CPL spectroscopy and, in particular, microscopy remain 
under-exploited, 
25
 the ability to separate these enantiomers easily when substituted with 
large groups at the 4-pyridyl position is likely to be rather useful in the development of chiral 
probes for future chiroptical studies. 
 
Sonogashira coupling reactions of tris(4-bromopyridyl) complexes 
The carbon-bromine bond in 4-substituted pyridine derivatives is activated towards oxidative 
addition by low-valent Pd species.  Indeed, the ligation of the pyridine lone pair to the 
europium(III) centre in [Eu.L
1
] may enhance this reactivity, as the europium can act as a 
charge sink stabilising any build up of charge in the heterocyclic ring. 
26
 Using a mixture of 
THF and DMF, it was possible to solubilise the active palladium-bisphospinoferrocenyl 
catalyst and the europium complex sufficiently to allow the alkyne coupling reaction to occur 
at 65°C (Scheme 2).  Using [Eu.L
1
] as the precursor, three different alkynes were coupled, to 
give the complexes, [Eu.L
3-5
], in 30-48% yield. Analysis of each Sonogashira reaction by 
LC-MS revealed quantitative conversion of [Eu.L
1
] to the desired tris-alkynyl product. 
However, loss of material in purification of each complex by reverse-phase HPLC 
contributed significantly to the moderate yields obtained.  
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  Scheme 2   Synthesis of the enantiopure complex [Eu.L6]  
 
Table 1    Selected photophysical data for Eu complexes (MeOH, 295 K) 
Complex max  nm   mM
-1
 cm
-1
 em % Eu ms 
[Eu.L
2
] 320 5.50 0.2 1.33 
[Eu.L
3
] 332 56.4 47 1.15 
[Eu.L
4
] 355 55.0 43 1.13 
[Eu.L
5
] 331 56.6 44 1.10 
[Eu.L
6
] 355 55.1 55 1.05 
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Using the analogous C-substituted complex, [Eu.L
1b
], derived from S-lysine and 76% 
enantiomercially pure (see ESI),
27
 the enantiopure complex, [Eu.L
6
] was prepared.  In 
methanol solution, each of these Eu complexes is particularly bright, with molar extinction 
coefficients of the order of 55 mM
-1
cm
-1
 and overall emission quantum yields of 44 to 55% 
(Table 1 and Figure 6). Such properties greatly accelerate the acquisition of CPL data, and 
the CPL spectrum of [Eu.L
6
] showed strong transitions in the J = 1 (589-600nm) and J = 4 
manifold (680 to 715 nm) in particular. The sequence and sign of the observed transitions 
were consistent 
23-25
 with formation of a  overall complex helicity, so that the complete 
stereochemical description of this complex is S--RRR--[Eu.L6]. Given that the 
brightness, B, of this complex in methanol is about 25 to 30 mM
-1
cm
-1
 and that the observed 
gem values are in the range 0.1 to 0.3 (Figure 6), this complex gives the strongest CPL signal 
yet observed for any lanthanide complex in solution, 
25
 allowing the spectrum to be acquired 
with good signal intensity over a period of 20 minutes, using a 3 M solution of the complex.   
 
 
 
 
 
 
 
 
 
Figure 6  left: absorption and total emission spectrum of [Eu.L
6
]; right: circularly polarised emission 
spectra of  (major/black) S-RRR--[Eu.L6], (MeOH, 295K, 3 M, 20 min;  gem = +0.30 (708 nm); +0.17 (655 
nm); -0.11 (598 nm)), and the enantiomeric -complex (red/minor) with an R stereogenic centre at C.    
 
Summary and Conclusions 
A tris-pyridyl-triazole-aryl Eu(III) complex and a set of four strongly emissive aralkynyl 
analogues can be synthesised from a common tris(4-bromopyridine) intermediate in one-pot 
reaction sequences. Given that, in the past, most sensitising groups in europium complexes 
have been integrated at an earlier stage in the synthetic route, the approach illustrated here 
offers much greater scope for the creation of larger families of complexes, as the route is 
inherently divergent.   For example, it can be anticipated that a wide range of functionality 
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may be incorporated into the aryl ring in each example, allowing interaction with targets of 
interest. Considering that the racemic complexes may be readily resolved by chiral HPLC, 
the generation of a series of enantiopure complexes for CPL investigations may also be 
envisaged.  
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Experimental  
X-Ray Crystallography. The data for compound [Eu.L
2
] were collected at 100.0 K on a 
Rigaku Saturn 724+ diffractometer at station I19 of the Diamond Light Source synchrotron 
(undulator,  = 0.6889 Å, -scan, 1.0°/frame, Cryostream (Oxford Cryosystems) nitrogen 
open-flow cryostat) and processed using Bruker APEXII software. The structure was solved 
by direct method and refined by full-matrix least squares on F
2
 for all data using SHELXTL
29
 
and OLEX2
30
 software. All non-disordered non-hydrogen atoms were refined anisotropically, 
the hydrogen atoms were placed in the calculated positions and refined in riding mode. 
Disordered atoms were refined isotropically with fixed SOF=0.5. The channels in the 
structure of [Eu.L
2
] contain a number of severely disordered solvent molecules 
(139e/independent part of the unit cell) that were taken into account by applying a MASK 
procedure in the OLEX2 program package. Crystallographic data for the structure have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication 
CCDC-982687.  
Crystal Data for [Eu.L
2
]: C54H61EuN15O11P3 (M=1341.05): monoclinic, space group C2/c 
(no. 15), a = 59.156(4), b = 13.3370(10), c = 18.5660(10)Å, β = 102.310(3)°, V = 
14311.1(16)Å
3
, Z = 8, T = 100.0(1) K, μ(Synchrotron)= 0.926 mm-1, Dcalc = 1.245g/mm3, 
56723 reflections measured (1.36 ≤ 2Θ ≤ 48.58), 11499 unique reflections (Rint = 0.0892) 
were used in all calculations. The final R1 was 0.0510 (7477>2σ(I)) and wR2 was 0.1309 (all 
data), GOF = 0.989.  
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NMR spectroscopy and mass spectrometry 
1
H, 
13
C, 
19
F and 
31
P NMR spectra were recorded in commercially-available deuteriated solvents on a 
Varian Mercury-200 (
1
H at 199.97 MHz, 
13
C at 50.29 MHz), Varian Mercury-400 or Bruker Avance-
400 (
1
H at 399.96 MHz, 
13
C at 100.57 MHz, 
31
P at 161.94 MHz), Varian Inova-500 (
1
H at 499.77 
MHz, 
13
C at 125.67 MHz,) or Varian VNMRS-700 (
1
H at 699.73 MHz,
 31
P at 283.26 MHz) 
spectrometer. Electrospray mass spectra were recorded on a Waters Micromass LCT or Thermo-
Finnigan LTQ FT instrument operating in positive or negative ion mode as stated, with methanol as 
the carrier solvent. Accurate mass spectra were recorded using the Thermo-Finnigan LTQ FT mass 
spectrometer.  
Alkyne synthesis:  3,4,5-Trimethoxyphenylacetylene 
1,1-Dibromo-2-(3,4,5-trimethoxyphenyl)-ethylene (1.41 g, 4.04 mmol) was dissolved in anhydrous 
THF (30 mL) and cooled to -78 °C. n-Butyl lithium (2.5 M in hexane, 6.4 mL, 16.2 mmol) was added 
slowly and the mixture was stirred at -78 °C under argon for 30 min. Water (8 mL) was added and the 
mixture was extracted with EtOAc (2 × 30 mL). The combined organic fractions were washed with 
half-strength brine solution (30 mL), dried (MgSO4), and the solvent was removed under reduced 
pressure. The residue thus obtained was subjected to column chromatography (silica gel; neat hexane, 
then hexane/EtOAc, 9:1 v/v) to give 3,4,5-trimethoxyphenylacetylene as a white solid (0.53 g, 68%); 
m.p. 71-73 °C (lit.
1
 m.p. 70-71 °C);
 1
H NMR (400 MHz, CDCl3) δ 6.72 (2H, s, H
4
), 3.85 (3H, s, H
8
), 
3.84 (6H, s, H
7
), 3.03 (1H, s, H
1
); 
13
C NMR (151 MHz, CDCl3) δ 153.1 (C
5
), 139.3 (C
6
), 117.0 (C
3
), 
109.4 (C
4
), 83.7 (C
2
), 76.2 (C
1
), 61.0 (C
8
), 56.2 (C
7
); (HRMS+) m/z 193.0845 [M + H]
+
 (C11H13O3 
requires 193.0865); Rf = 0.45 (silica; hexane/EtOAc 4:1 v/v). The spectral data were consistent with 
those reported previously.
28 
 
tert-Butyl (4-formyl-3,5-dimethoxyphenoxy)acetate 
To a solution of 4-hydroxy-2,6-dimethoxybenzaldehyde (1.00 g, 5.49 mmol) in a 
dichloromethane/dimethylformamide mixture (5:1, 36 mL) under argon was added potassium 
carbonate (1.52 g, 11.0 mmol) and tert-butyl bromoacetate (1.62 mL, 2.14 g, 11.0 mmol). The 
mixture was stirred for 24 h at which point the potassium carbonate was removed by gravity filtration. 
The dichloromethane was removed under reduced pressure and the dimethylformamide was removed 
by vacuum distillation to give the product as a white solid (1.35 g, 83%), which was used without 
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further purification; m.p. 130-132 °C; 
1
H NMR (400 MHz, CDCl3) δ 1.50 (9 H, s, H
9
), 3.86 (6 H, s, 
H
10
), 4.57 (2 H, s, H
6
), 6.08 (2 H, s, H
4
), 10.35 (1 H, s, H
1
); 
13
C NMR (101 MHz, CDCl3) δ 28.2, 56.2, 
65.7, 83.2, 91.0, 109.5 164.2, 164.4, 167.2, 187.9; LRMS (ESI) m/z 297 [M + H]
+
; (HRMS
+
) m/z 
297.1331 [M + H]
+
 (C15H21O6) requires 297.1338.  
 
tert-Butyl [4-(2,2-dibromoethenyl)-3,5-dimethoxyphenoxy]acetate  
To a solution of triphenylphosphine (4.62 g, 17.6 mmol) and tetrabromomethane (2.92 g, 8.8 mmol) 
in anhydrous dichloromethane (15 mL) under argon at 0 °C was added a solution of tert-butyl (4-
formyl-3,5-dimethoxyphenoxy)acetate (1.30 g, 4.4 mmol) in anhydrous dichloromethane (15 mL). 
The resulting red solution was stirred for 18 hours. The solvent was removed under reduced pressure 
and the residue was stirred in diethyl ether, filtered and concentrated under reduced pressure. The 
crude product was purified by column chromatography (silica, neat hexane to 5:1 v/v hexane/ethyl 
acetate) to give the product as a white solid (1.22 g, 62%); m.p. 122-124 °C; 
1
H NMR (400 MHz, 
CDCl3) δ 1.50 (9 H, s, H
10
), 3.79 (6 H, s, H
11
), 4.52 (2 H, s, H
7
), 6.11 (2 H, s, H
5
), 7.17 (1 H, s, H
2
); 
13
C NMR (101 MHz, CDCl3) δ 28.2, 55.8, 65.9, 82.7, 91.3, 93.1, 107.8, 130.9, 158.1, 160.1, 167.9; 
LRMS (ESI) m/z 451; (HRMS
+
) m/z 450.9771 [M + H]
+
 (C16H21O6
79
Br2) requires 450.9756. 
 
tert-Butyl (4-ethynyl-3,5-dimethoxyphenoxy)acetate 
To a solution of tert-Butyl [4-(2,2-dibromoethenyl)-3,5-dimethoxyphenoxy]acetate (0.797 g, 1.77 
mmol) in dry THF (20 mL) under argon at -78 °C, was added n-butyllithium (1.42 mL of a 2.5 M 
solution, 3.54 mmol). The solution was stirred for 30 min when a further 0.5 eq. of n-butyllithium was 
added. The mixture was stirred for a further 15 min before water (20 mL) was added. THF was 
removed under reduced pressure and the remaining aqueous solution was extracted into 
dichloromethane (3 x 30 mL). The organic layers were combined, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by column chromatography 
(silica, hexane/ethyl acetate 8:1 v/v) to give the product as a white solid (0.248 g, 48%); m.p. 107-108 
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°C; 
1
H NMR (700 MHz, CDCl3) δ 1.49 (9 H, s, H
10
), 3.49 (1 H, s, H
1
), 3.86 (6 H, s, H
11
), 4.53 (2 H, s, 
H
7
), 6.11 (2 H, s, H5); 
13
C NMR (176 MHz, CDCl3) δ 28.2 (C
9
), 56.3  (C
11
), 65.9 (C
7
), 76.4 (C
2
), 82.9 
(C
9
), 84.2 (C
1
), 91.2 (C
5
), 94.1 (C
3
), 160.2 (C
6
), 163.1 (C
4
), 167.6 (C
8
); LRMS (ESI) m/z 293 [M + 
H]
+
; (HRMS
+
) m/z 293.1390 [M + H]
+
 (C16H21O6) requires 293.1389. 
Ligand and Complex synthesis 
[Eu.L
1
]  
The synthesis of the tris p-bromo Eu(III) complex [Eu.L
1
] has been reported elsewhere.
23
  
1
H NMR 
(400 MHz, CD3OD) δ 8.60 (1H, s, pyH), 7.97 (1H, s, pyCHN), 7.12 (1H, s, pyH), 4.36 (1H, s, 
NCH’eq), 0.54 (3H, s, CH3), -0.77 (1H, s, pyCH’N), -1.37 (1H, s, NCH’ax), -2.23 (1H, s, NCHeq), -5.28 
(1H, s, NCHax). 
31
P NMR (162 MHz, CD3OD) +39.8. m/z (HRMS
+
) 1020.851 [M + H]
+
 
(C27H34
79
Br3N6O6P3
151
Eu requires 1020.849). Rf = 0.31 (silica;  CH2Cl2/CH3OH/ aq. ammonia: 
82/15/3 : v/v/v)  
[Eu.L
2
] 
CAUTION! Care should be taken using azides and (poly)triazoles, particularly if scaling up the 
reaction conditions stated here. 
 
To a solution of [Eu.L
1
] (5.0 mg, 4.9 mol) in DMF (0.5 mL), NaN3 (3.8 mg, 59 mol) was added. 
The reaction was heated to 70 C, and monitored by LC-MS until full substitution of the three 
bromines was complete (within 16 h). The reaction was cooled to RT, and 4-ethynylanisole (2.9 mg, 
22 mol), TBTA (1.6 mg, 2.9 mol), CuSO4.5H2O (0.7 mg, 2.9 mol) in H2O (0.5 mL) and sodium 
ascorbate (1.2 mg, 5.9 mol) were added, and the progress of the reaction monitored by LC-MS. Full 
conversion was observed within 1 h, with the solution darkening from very pale yellow to pale green 
over this time. The reaction mixture was evaporated onto silica, and the material purified by silica gel 
chromatography (silica, CH2Cl2 : CH3OH 95 : 5 to 80 : 20; Rf = 0.15, CH2Cl2 : CH3OH 90 : 10), then 
reverse phase HPLC (XBridge C18 10 cm 3.5 m, H2O / CH3OH with 0.1 % HCOOH gradient 
elution), to give the tris-triazole complex as a white solid (1.0 mg, isolated yield 16 %). 
H (400 MHz, CD3OD) 9.34, 8.94, 7.96, 7.47, 7.11 (s+s +s +s +s +s, ArCH and triazole CH)  7.90 
(3H, br s pyCH); 4.55 (3H, br s, CHeq’); 3.89 (9H s, OMe); 0.84 (9H, br s, PMe); -0.51 (3H br s, 
CHpy’); -1.11 (3H, br s Hax’); -1.71 (3H, br s Heq); -4.95 (3H, br s, Hax)P (162 MHz, CD3OD) 
+39.2.m/z (HRMS+) 1304.296 [M + H]+ (C54H58N15O9P3
151
Eu requires 1304.297). 
 max (MeOH) = 320 nm (5500 M
-1
cm
-1
);   (CH3OH) 1.33 ms; em (MeOH) 0.2 %.   
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RP- HPLC: tR = 9.7 min (XBridge C18 10 cm 3.5 m, H2O / CH3OH with 0.1 % HCOOH [gradient 
elution, see Table below for details], 1 mL/min,  = 320 nm, 293 K). 
 
Details of the reverse phase HPLC eluant gradient: 
Time / min H2O (+ 0.1 % HCOOH) MeOH (+ 0.1 % HCOOH) Curve 
2.0 60 40 0 
10.0 5 95 1 
2.0 5 95 0 
0.5 90 10 1 
2.0 90 10 0 
 
Chiral HPLC: tR = 22.7 min and 61.4 min (CHIRALPAK-ID, 4.0 mm × 250 mm, CH3OH, 1 mL/min, 
295 K). On the semi-preparative column at 2.5 mL/min, the complexes eluted after 87 and 226 
minutes. By analysis of the CPL emission signature with related complexes of established helicity, the 
first eluted complex was assigned the  absolute configuration. 23,24,25  
     
[Eu.L
3
] 
To a stirred, degassed solution of the tris p-bromo Eu(III) complex [Eu.L
1
] (5 mg, 4.9 mol) in a 
mixture of anhydrous THF/DMF (2:3 v/v, 500 L) was added 3,4,5-trimethoxyphenylacetylene (3.1 
mg, 16.1 mol) and triethylamine (14 L, 98 mol), and the solution was degassed (freeze-thaw 
cycle) three times. [1,1-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.2 mg, 1.47 mol) 
and CuI (0.3 mg, 1.5 mol) were added and the resulting yellow solution was stirred at 65 °C under 
argon for 12 h. After this time the solution turned dark brown and LC-MS analysis revealed complete 
conversion of starting material. The solvent was removed under reduced pressure and the brown 
residue was purified by semi-preparative RP-HPLC [gradient: 50 − 100% methanol in water (0.1% 
formic acid) over 10 min; tR = 9.8 min] to give a white solid (2.6 mg, 40%); LRMS (ESI) m/z 1355 
[M + H]
+
, 678 [M + 2H]
2+
; (HRMS
+
) m/z 1355.305 [M(
151
Eu) + H]
+
 (C60H67N6O15P3
151
Eu requires 
1355.308); MeOH   1.15 ms and 0.91 ms (H2O); 
em
MeOH  47 (± 15)%;  εMeOH (332 nm) = 56,400 M
-
1
 cm
-1
.  tR = 9.8 min (50 to 100% MeOH in water + 0.1 % formic acid). 
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Triethyl 6,6',6''-((S)-2-(4-(cyclohexanecarboxamido)butyl)-1,4,7-triazacyclononane-
1,4,7-triyl)tris(methylene)tris(4-bromopyridine-6,2-diyl)tris(methylphosphinate), L
1b
 
     
(S)-N-(4-(1,4,7-Triazacyclononan-2-yl)butyl)cyclohexanecarboxamide 
27
 (75 mg, 0.24 
mmol), was added to a solution of (4-bromo-6-(ethoxy(methyl)phosphoryl)pyridin-2-
yl)methyl methanesulfonate (320 mg, 0.86 mmol) and K2CO3 (198 mg, 1.47 mmol) in dry 
CH3CN (15 mL) and stirred under argon at 65 °C. After 6 h the solution was allowed to cool 
to RT and filtered. The filtrate was concentrated and purified by HPLC (Method A, tR = 8.5 
min) to give a yellow oil as a mixture of diastereoisomers, (65 mg, 25 %); H (CDCl3) 8.20-
7.82 (6H, m, py), 6.45 (1H, br, CONH), 4.17-3.87 (12H, m, POCH2 and H
17-17’-17’’
), 3.23-2.59 
(13H, m, H
2-3-5-6-8-9-13
), 1.82-1.76 (9H, m, PCH3), 1.76-1.26 (26H, m, CH3(Et) and H
10-11-12-14-
15-16-17
); P (CDCl3) + 37.76; m/z (HRMS
+
) 1138.191 [M + H]
+
 (C44H68
79
Br3N7O7P3 requires 
1138.193). 
Europium (III) complex of (S)-6,6',6''-(2-(4-(cyclohexanecarboxamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-bromopyridine-6,2-
diyl)tris(methylphosphinate),  [Eu.L
1b
] 
     
Triethyl 6,6',6''-((S)-2-(4-(cyclohexanecarboxamido)butyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-bromopyridine-6,2-diyl)tris(methylphosphinate) (10 mg, 8.8 mol) 
was dissolved in CD3OD (3 mL) and a solution of 0.1 M NaOH in D2O (1 mL) was added. 
The mixture was heated to 90 °C under argon and monitored with 
31
P-NMR [P(reactant) = 
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38.8, (P(product) = 25.9]. After 5 h the solution was cooled to RT and the pH was adjusted 
to 7 with HCl. Eu(AcO)3H2O (3.2 mg, 9.7mol) was added and the mixture heated to 65 °C 
overnight under argon. The solvent was removed under reduced pressure and the product 
purified by column chromatography (silica, CH2Cl2 : CH3OH : NH3 9 : 1: 0.1) giving the title 
compound as a white solid (5 mg, 50 %); P (CD3OD) 43.4, 40.7, 37.5; m/z (HRMS
+
) 
1203.995 [M + H]
+
 (C38H53
79
Br3
153
EuN7O7P3 requires 1203.995); Rf = 0.32 (silica, 
CH2Cl2 : CH3OH : NH3, 9 : 1: 0.1 (v/v)). 
 
Europium (III) complex of (S)-6,6',6''-(2-(4-(cyclohexanecarboxamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris-4-[2-(2,4,6-trimethoxyphenyl)ethynyl]pyridin-
6,2-diyl)tris(methylphosphinate) [Eu.L
6
] 
    
To a stirred degassed solution of the tris p-bromo Eu(III) complex [Eu.L
2
] (0.6 mg, 0.50 mol) in a 
mixture of anhydrous THF/DMF (1:1 v/v, 400 mL) was added 2,4,6-trimethoxyphenylacetylene (0.3 
mg, 1.5 mol) and triethylamine (1.0 mL, 7.50 mol), and the solution was degassed (freeze-thaw 
cycle) three times. [1,1-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (250 g, 0.3 mmol) 
and CuI (60 g, 0.3 mmol) were added and the resulting yellow solution was stirred at 65 °C under 
argon for 12 h. LC-MS analysis at this time revealed complete conversion of starting material. The 
solvent was removed under reduced pressure and the brown residue was purified by semi-preparative 
RP-HPLC [gradient: 50 − 100% methanol in water (0.1% formic acid) over 15 min; tR = 11.4 min] to 
give [Eu.L
2
] as a white solid (0.33 mg, 51%); LRMS (ESI) m/z 1538 [M + H]
+
, 770 [M + 2H]
2+
; 
(HRMS
+
) m/z  769.7291 [M(
153
Eu) + 2H]
2+
 (C71H87N7O16P3
153
Eu requires 769.7322); MeOH   1.05 
ms; e mM e OH 55 (± 15)%; 2
em
H O  10 (± 15)%; εMeOH (355 nm) = 55,100 M
-1
 cm
-1
.  
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